(Q53624114)

16 May 2018

title

Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. (English)

1 reference

16 May 2018

0 references

0 references

0 references

0 references

1

1 reference

16 May 2018

Mohsen Khademi

3

1 reference

16 May 2018

Clas Malmeström

6

1 reference

16 May 2018

Kaj Blennow

5

object named as

Kaj Blennow

1 reference

16 May 2018

4

Henrik Zetterberg

1 reference

16 May 2018

Markus Axelsson

2

1 reference

16 May 2018

Fredrik Piehl

7

1 reference

16 May 2018

Tomas Olsson

8

1 reference

16 May 2018

Jan Lycke

9

1 reference

16 May 2018

publication date

11 July 2016

1 reference

16 May 2018

Multiple Sclerosis Journal

published in

1 reference

16 May 2018

volume

23

1 reference

16 May 2018

issue

1

1 reference

16 May 2018

page(s)

62-71

1 reference

16 May 2018

Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Mu

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

Cell-selective knockout and 3D confocal image analysis reveals separate roles for astrocyte-and endothelial-derived CCL2 in neuroinflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458516639384

21 January 2018

Identifiers

DOI

10.1177/1352458516639384

1 reference

16 May 2018

1 reference

16 May 2018